FYERS
Home
/
Stocks
/
Profit Loss
/
Strides Pharma Science Profit & Loss

Strides Pharma Science Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021Dec 2020Sep 2020Jun 2020Mar 2020Dec 2019Sep 2019Jun 2019Mar 2019Dec 2018Sep 2018Jun 2018Mar 2018Dec 2017Sep 2017Jun 2017Mar 2017Dec 2016Sep 2016Jun 2016Mar 2016Dec 2015Sep 2015Jun 2015Mar 2015Dec 2014Sep 2014Jun 2014Dec 2012Sep 2012Jun 2012Mar 2012Dec 2011Sep 2011
₹1265 Cr₹1323 Cr₹1195 Cr₹1221 Cr₹1120 Cr₹1190 Cr₹1154 Cr₹1167 Cr₹1054 Cr₹1044 Cr₹1006 Cr₹999 Cr₹930 Cr₹986 Cr₹865 Cr₹897 Cr₹940 Cr₹866 Cr₹794 Cr₹721 Cr₹688 Cr₹908 Cr₹832 Cr₹794 Cr₹782 Cr₹619 Cr₹732 Cr₹715 Cr₹686 Cr₹616 Cr₹570 Cr₹520 Cr₹473 Cr₹670 Cr₹749 Cr₹769 Cr₹658 Cr₹677 Cr₹730 Cr₹872 Cr₹790 Cr₹924 Cr₹868 Cr₹715 Cr₹613 Cr₹1515 Cr₹319 Cr₹287 Cr₹254 Cr₹633 Cr₹596 Cr₹551 Cr₹534 Cr₹687 Cr₹774 Cr
₹5 Cr₹8 Cr₹107 Cr₹27 Cr₹9 Cr₹12 Cr₹6 Cr₹28 Cr₹13 Cr-₹14 Cr₹9 Cr₹36 Cr₹9 Cr₹27 Cr₹26 Cr₹23 Cr₹14 Cr₹86 Cr₹10 Cr₹22 Cr₹19 Cr₹13 Cr₹14 Cr₹18 Cr₹16 Cr₹18 Cr₹14 Cr₹14 Cr₹10 Cr₹17 Cr₹10 Cr₹10 Cr₹6 Cr₹16 Cr₹16 Cr₹22 Cr₹34 Cr₹62 Cr₹22 Cr₹55 Cr₹21 Cr₹28 Cr₹9 Cr₹52 Cr₹29 Cr₹14 Cr₹10 Cr₹10 Cr₹13 Cr₹18 Cr₹7 Cr₹9 Cr₹6 Cr₹13 Cr₹6 Cr
₹1270 Cr₹1332 Cr₹1302 Cr₹1248 Cr₹1128 Cr₹1202 Cr₹1159 Cr₹1195 Cr₹1067 Cr₹1030 Cr₹1015 Cr₹1035 Cr₹939 Cr₹1013 Cr₹891 Cr₹921 Cr₹954 Cr₹952 Cr₹805 Cr₹744 Cr₹707 Cr₹922 Cr₹846 Cr₹811 Cr₹798 Cr₹636 Cr₹746 Cr₹729 Cr₹696 Cr₹633 Cr₹580 Cr₹529 Cr₹479 Cr₹686 Cr₹764 Cr₹791 Cr₹692 Cr₹740 Cr₹752 Cr₹927 Cr₹810 Cr₹952 Cr₹877 Cr₹767 Cr₹642 Cr₹1528 Cr₹329 Cr₹297 Cr₹267 Cr₹651 Cr₹603 Cr₹559 Cr₹540 Cr₹700 Cr₹780 Cr
₹1092 Cr₹1137 Cr₹1009 Cr₹1039 Cr₹951 Cr₹1021 Cr₹992 Cr₹1031 Cr₹911 Cr₹887 Cr₹913 Cr₹906 Cr₹823 Cr₹892 Cr₹809 Cr₹861 Cr₹940 Cr₹885 Cr₹854 Cr₹792 Cr₹799 Cr₹803 Cr₹725 Cr₹689 Cr₹680 Cr₹599 Cr₹595 Cr₹610 Cr₹608 Cr₹553 Cr₹537 Cr₹506 Cr₹459 Cr₹622 Cr₹656 Cr₹698 Cr₹621 Cr₹585 Cr₹619 Cr₹762 Cr₹700 Cr₹858 Cr₹755 Cr₹647 Cr₹573 Cr₹1356 Cr₹275 Cr₹244 Cr₹225 Cr₹536 Cr₹476 Cr₹445 Cr₹424 Cr₹610 Cr₹649 Cr
₹235 Cr₹248 Cr₹343 Cr₹259 Cr₹227 Cr₹230 Cr₹216 Cr₹213 Cr₹203 Cr₹191 Cr₹151 Cr₹189 Cr₹175 Cr₹183 Cr₹143 Cr₹122 Cr₹74 Cr₹128 Cr₹12 Cr₹9 Cr-₹37 Cr₹170 Cr₹174 Cr₹175 Cr₹167 Cr₹83 Cr₹194 Cr₹161 Cr₹131 Cr₹109 Cr₹71 Cr₹54 Cr₹49 Cr₹108 Cr₹147 Cr₹130 Cr₹106 Cr₹192 Cr₹164 Cr₹209 Cr₹153 Cr₹134 Cr₹162 Cr₹156 Cr₹101 Cr₹243 Cr₹70 Cr₹68 Cr₹56 Cr₹145 Cr₹156 Cr₹140 Cr₹139 Cr₹120 Cr₹153 Cr
₹41 Cr₹42 Cr₹43 Cr₹46 Cr₹47 Cr₹50 Cr₹52 Cr₹74 Cr₹73 Cr₹71 Cr₹70 Cr₹79 Cr₹76 Cr₹81 Cr₹58 Cr₹68 Cr₹55 Cr₹49 Cr₹42 Cr₹44 Cr₹41 Cr₹42 Cr₹35 Cr₹37 Cr₹37 Cr₹40 Cr₹40 Cr₹40 Cr₹35 Cr₹23 Cr₹22 Cr₹17 Cr₹17 Cr₹45 Cr₹50 Cr₹49 Cr₹52 Cr₹48 Cr₹44 Cr₹58 Cr₹56 Cr₹62 Cr₹54 Cr₹34 Cr₹28 Cr₹84 Cr₹9 Cr₹13 Cr₹10 Cr₹45 Cr₹46 Cr₹51 Cr₹39 Cr₹52 Cr₹49 Cr
₹201 Cr₹147 Cr₹246 Cr₹154 Cr₹122 Cr₹103 Cr₹113 Cr₹87 Cr₹182 Cr₹64 Cr₹22 Cr-₹115 Cr₹33 Cr₹34 Cr₹65 Cr₹7 Cr-₹107 Cr-₹59 Cr-₹107 Cr-₹151 Cr-₹225 Cr₹76 Cr₹73 Cr₹98 Cr₹126 Cr-₹173 Cr₹127 Cr₹162 Cr₹46 Cr₹72 Cr₹35 Cr₹70 L₹56 L-₹3 Cr₹53 Cr₹32 Cr₹15 Cr₹99 Cr₹77 Cr₹94 Cr₹49 Cr₹43 Cr₹68 Cr₹69 Cr₹19 Cr₹65 Cr₹45 Cr₹48 Cr₹27 Cr₹77 Cr₹82 Cr₹109 Cr₹681 Cr₹87 Cr₹53 Cr
₹167 Cr₹128 Cr₹208 Cr₹133 Cr₹105 Cr₹82 Cr₹89 Cr₹73 Cr₹3351 Cr₹45 Cr₹67 Cr-₹107 Cr₹24 Cr₹27 Cr₹61 Cr₹64 Cr-₹79 Cr₹73 Cr-₹102 Cr-₹145 Cr-₹189 Cr₹64 Cr₹62 Cr₹107 Cr₹123 Cr-₹162 Cr₹116 Cr₹163 Cr₹21 Cr₹65 Cr₹303 Cr₹3 Cr₹4 Cr₹583 Cr₹91 Cr₹17 Cr₹9 Cr₹131 Cr₹196 Cr₹86 Cr₹33 Cr₹5 Cr₹58 Cr₹38 Cr₹12 Cr₹52 Cr₹19 Cr-₹43 Cr₹19 Cr₹62 Cr₹52 Cr₹90 Cr₹642 Cr₹73 Cr₹47 Cr

Share Price Live Stats

Open (₹)1,087.00
Volume (₹)66,672.00
High (₹)1,091.10
Upper Circuit1,314.60
Low (₹)1,075.50
Lower Circuit876.40
Prev Close1,095.50
52W High (₹)1,260.90
Price1,082.00
52W Low (₹)768.65

Share Market Cap & Key Ratios Overview

M.Cap (₹)10121.00 Cr
Div. Yield (%)0.46
PE Ratio16.50
Debt to Equity0.54
Price to Book2.78
Book Value337.08
EPS (TTM)66.56
Face Value10.00
ROE (%)20.31

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
LAURUSLABSNSE
CIPLANSE
DRREDDYNSE
MANKINDNSE
AUROPHARMANSE
LUPINNSE
STARNSE
LTP
1W Low
1W High
Market cap (₹)
1750-10 (-0.57%)
1743.10
1776.60
4,24,466Cr
9156.5-183.5 (-1.96%)
9060
9431.50
2,46,222Cr
4599.1-57.8 (-1.24%)
4551.80
4682
1,76,301Cr
1127.2+9.7 (0.87%)
1107.30
1139.80
1,12,818Cr
2043.7+7.1 (0.35%)
2007.80
2069.20
1,10,823Cr
1316+15 (1.15%)
1300.20
1333.30
1,07,447Cr
1219.8+22.8 (1.90%)
1196.90
1250.70
1,03,471Cr
2337-31.5 (-1.33%)
2328.10
2426.80
97,850Cr
1678.5-14.5 (-0.86%)
1660.10
1715
96,836Cr
1946.2-10.3 (-0.53%)
1925.70
1964.90
89,629Cr
1082-3.3 (-0.30%)
1063
1107
10,121Cr
Empty box

No content available